CERo Therapeutics (CERO) News Today $0.53 -0.05 (-8.90%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.53 +0.00 (+0.57%) As of 06:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy RecommendationMay 20 at 8:30 AM | msn.comMaxim Group Begins Coverage on CERo Therapeutics (NASDAQ:CERO)May 20 at 2:11 AM | americanbankingnews.comCERo Therapeutics (NASDAQ:CERO) Stock Price Up 1.5% - Here's What HappenedMay 16, 2025 | americanbankingnews.comCERo Therapeutics regains Nasdaq compliance, eyes trialsMay 9, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)May 8, 2025 | investing.comCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)May 8, 2025 | globenewswire.comCERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid LeukemiaMay 3, 2025 | nasdaq.comCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical ...April 30, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical ...April 30, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 30, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER ...April 26, 2025 | seekingalpha.comCERo Therapeutics Announces Clinical Trial Partnership with Sarah Cannon Research Institute for Phase 1 Trial of CER-1236 in Acute Myeloid LeukemiaApril 26, 2025 | nasdaq.comCero Therapeutics to present on CER-1236 at ASCO meetingApril 26, 2025 | markets.businessinsider.comCERo announces SCRI as main site for trial of CER-1236 to treat AMLApril 26, 2025 | msn.comCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American ...April 25, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American ...April 25, 2025 | gurufocus.comCero Therapeutics announces SCRI at CBCI as key trial site for Phase 1 trialApril 25, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingApril 25, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 24, 2025 | globenewswire.comCERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy ProgramsApril 23, 2025 | nasdaq.comCero Therapeutics initiated with a Buy at D. Boral CapitalApril 23, 2025 | markets.businessinsider.comCero Therapeutics enters securities purchase agreement for up to $8MApril 23, 2025 | markets.businessinsider.comD. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy RecommendationApril 22, 2025 | msn.comCERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy DevelopmentApril 22, 2025 | quiverquant.comCERo Therapeutics, Inc. Announces Up to $8 Million Series D FinancingApril 22, 2025 | globenewswire.comCERo Therapeutics expands patent portfolio with new US approvalsApril 12, 2025 | uk.investing.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236April 12, 2025 | seekingalpha.comCero Therapeutics announces critical patent application allowances from USPTOApril 10, 2025 | markets.businessinsider.comCero announces initial clinical trial site for Phase 1 trial of CER-1236April 10, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. ...April 10, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236April 10, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236April 10, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 9, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaApril 9, 2025 | globenewswire.comCERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid TumorsApril 2, 2025 | nasdaq.comCero Therapeutics receives FDA clearance of second IND application for CER-1236April 1, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid TumorsMarch 31, 2025 | globenewswire.comCero Therapeutics set to initiate enrollment of Phase 1 trial of CER-1236March 29, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of ManufacturingMarch 27, 2025 | globenewswire.comCERo enters manufacturing agreement with University of California DavisMarch 20, 2025 | markets.businessinsider.comCERO Flat on Leukemia Drug DevelopmentsMarch 19, 2025 | baystreet.caCERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays BullishMarch 19, 2025 | msn.comCERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in ...March 19, 2025 | gurufocus.comCERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing ServicesMarch 19, 2025 | globenewswire.comCERo Therapeutics reveals promising preclinical ovarian cancer studyMarch 15, 2025 | uk.investing.comCero Therapeutics presents preclinical data on CER-1236 at SITC Spring meetingMarch 14, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors MeetingMarch 13, 2025 | globenewswire.comCero Therapeutics announces progress in initiation of Phase 1 trialMarch 6, 2025 | markets.businessinsider.comCERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational AssaysMarch 6, 2025 | globenewswire.comCERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14March 5, 2025 | globenewswire.com Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address CERO Media Mentions By Week CERO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERO News Sentiment▼0.480.65▲Average Medical News Sentiment CERO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERO Articles This Week▼51▲CERO Articles Average Week Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RLMD News TRIB News SYBX News ERNA News MRKR News CLDI News RLYB News HOTH News NXTC News IMNN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
